Catalog No.
DXX00402
Expression system
Mammalian Cells
Species reactivity
Bacillus anthracis
Host species
Human
Isotype
IgG1-lambda
Clonality
Monoclonal
Target
Protective antigen, PA, Anthrax toxins translocating protein, PA-83, PA83, Protective antigen PA-20, PA-20, PA20, Protective antigen PA-63, PA-63, PA63, pagA, pag, pXO1-110, BXA0164, GBAA_pXO1_0164
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P13423
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CAS: 565451-13-0
Clone ID
Raxibacumab
Raxibacumab, PMID: 20068396
Raxibacumab: a panacea for anthrax disease?, PMID: 32333846
Raxibacumab for anthrax, PMID: 23545582
Raxibacumab: potential role in the treatment of inhalational anthrax, PMID: 24812521
Raxibacumab, PMID: 33886175
Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study, PMID: 32333847
Raxibacumab for the treatment of inhalational anthrax, PMID: 19587338
Raxibacumab for inhalational anthrax: an effective specific therapeutic approach?, PMID: 20450444
Raxibacumab augments hemodynamic support and improves outcomes during shock with B. anthracis edema toxin alone or together with lethal toxin in canines, PMID: 26097803
Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax, PMID: 25487792
Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration "Animal Rule", PMID: 26648915
Population pharmacokinetics of raxibacumab in healthy adult subjects, PMID: 33973655
Pharmacology and Anti-infective Role of Raxibacumab: A Novel Monoclonal Antibody for the Treatment of Anthrax, PMID: 28358441
Teriflunomide, PMID: 24421467
Extrapolation and dosing recommendations for raxibacumab in children from birth to age <18 years, PMID: 33974281
Anthrax Antitoxins, PMID: 31644058
Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits, PMID: 23344456
Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy, PMID: 28856066
Obiltoxaximab (Anthim) for inhalation anthrax, PMID: 30383733
Bacillus anthracis infections--new possibilities of treatment, PMID: 26094508
Designing inhibitors of anthrax toxin, PMID: 24447197
Pharmaceutical approval update, PMID: 23599674
Development trends for human monoclonal antibody therapeutics, PMID: 20811384
A systematic review and meta-analysis of preclinical trials testing anti-toxin therapies for B. anthracis infection: A need for more robust study designs and results, PMID: 28797061
Monoclonal Antibodies Against Infectious Microbes: So Long and Too Little!, PMID: 32164518
Antitoxin Treatment of Inhalation Anthrax: A Systematic Review, PMID: 26690378
A Review of the Efficacy of FDA-Approved B. anthracis Anti-Toxin Agents When Combined with Antibiotic or Hemodynamic Support in Infection- or Toxin-Challenged Preclinical Models, PMID: 33450877
Alternative pre-approved and novel therapies for the treatment of anthrax, PMID: 27809794
Bacillus anthracis Edema Toxin Increases Fractional Free Water and Sodium Reabsorption in an Isolated Perfused Rat Kidney Model, PMID: 28438974
Passive Immunotherapy Protects against Enteric Invasion and Lethal Sepsis in a Murine Model of Gastrointestinal Anthrax, PMID: 26426050
Pediatric anthrax clinical management: executive summary, PMID: 24777221
Protecting against future shock--inhalational anthrax, PMID: 19587345
Animal rule for drug approval creates a jungle of confusion, PMID: 23389593
Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women, PMID: 24457117
Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults, PMID: 24447897
New drugs 2014, part 2, PMID: 24905857
For research use only. Not for human or drug use.
